WO2014111790A2 - Stable transdermal pharmaceutical drug delivery system comprising rivastigmine - Google Patents
Stable transdermal pharmaceutical drug delivery system comprising rivastigmine Download PDFInfo
- Publication number
- WO2014111790A2 WO2014111790A2 PCT/IB2014/000029 IB2014000029W WO2014111790A2 WO 2014111790 A2 WO2014111790 A2 WO 2014111790A2 IB 2014000029 W IB2014000029 W IB 2014000029W WO 2014111790 A2 WO2014111790 A2 WO 2014111790A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivery system
- drug delivery
- rivastigmine
- transdermal drug
- pharmaceutically acceptable
- Prior art date
Links
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 title claims abstract description 73
- 229960004136 rivastigmine Drugs 0.000 title claims abstract description 69
- 238000012377 drug delivery Methods 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 26
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 22
- 238000003860 storage Methods 0.000 claims abstract description 18
- 206010012289 Dementia Diseases 0.000 claims abstract description 12
- 238000010521 absorption reaction Methods 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 58
- 238000013271 transdermal drug delivery Methods 0.000 claims description 47
- 239000000853 adhesive Substances 0.000 claims description 37
- 230000001070 adhesive effect Effects 0.000 claims description 37
- -1 polyisoalkylenes Polymers 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 29
- 238000009472 formulation Methods 0.000 claims description 22
- 229920002367 Polyisobutene Polymers 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 239000004014 plasticizer Substances 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 5
- 230000035515 penetration Effects 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims description 4
- 229940108366 exelon Drugs 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 239000005062 Polybutadiene Substances 0.000 claims description 2
- 229920002614 Polyether block amide Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000002174 Styrene-butadiene Substances 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 claims description 2
- 229920001971 elastomer Polymers 0.000 claims description 2
- 229920002857 polybutadiene Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000005060 rubber Substances 0.000 claims description 2
- 229920006132 styrene block copolymer Polymers 0.000 claims description 2
- 239000011115 styrene butadiene Substances 0.000 claims description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 25
- 238000000034 method Methods 0.000 abstract description 12
- 239000010410 layer Substances 0.000 description 31
- 235000006708 antioxidants Nutrition 0.000 description 24
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000012790 adhesive layer Substances 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000010525 oxidative degradation reaction Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000010030 laminating Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229940123973 Oxygen scavenger Drugs 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 239000004811 fluoropolymer Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940059904 light mineral oil Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000013464 silicone adhesive Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- BXCRLBBIZJSWNS-UHFFFAOYSA-N 2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCO BXCRLBBIZJSWNS-UHFFFAOYSA-N 0.000 description 1
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
- QDQHWKZZJJDBND-UHFFFAOYSA-M 4-ethyl-4-hexadecylmorpholin-4-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.CCCCCCCCCCCCCCCC[N+]1(CC)CCOCC1 QDQHWKZZJJDBND-UHFFFAOYSA-M 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- IOBZMMXOKDNXPQ-UHFFFAOYSA-N dodecanamide;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCC(N)=O IOBZMMXOKDNXPQ-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 239000005001 laminate film Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002954 polymerization reaction product Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical class O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000130 skin irritation / corrosion testing Toxicity 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
Definitions
- the present invention relates to a stable transdermal pharmaceutical drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, which is free from an antioxidant.
- the present invention relates to a stable transdermal pharmaceutical drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, which provides an enhanced absorption of drug through skin, and remains stable during a longer storage period.
- the present invention relates to a method of treatment of mild to moderate dementia of alzheimer's type and mild to moderate dementia of parkinson's type diseases.
- Rivastigmine is a reversible cholinesterase inhibitor (parasympathomimetic or cholinergic agent) that has been approved for the treatment of mild to moderate dementia of the alzheimer's type, and mild to moderate dementia associated with parkinson's disease.
- Rivastigmine is known to be susceptible to degradation by oxygen from the environmental oxidation.
- Various pharmaceutical compositions comprising rivastigmine has been proposed in the prior art, claiming the use of antioxidants, particular carriers or excipients and packaging material containing oxygen scavengers to stabilize the formulation.
- GB Patent Number 2203040 discloses transdermal composition of rivastigmine containing mixture of Eudragit E 100, DuroTak 280 - 2416 polymers and a plasticizer Brij 97. Such composition was found to degrade, possibly by oxidative degradation, despite the formation of an occlusive polymer matrix around the rivastigmine and its storage in air tight packaging.
- U.S. Patent Number 6,335,031 and 6,660,295 disclose a pharmaceutical composition comprising rivastigmine in free base or acid addition salt form and an antioxidant to prevent oxidative degradation of rivastigmine. Such formulations found to be stable for a longer period of time.
- WO 2012/012417 discloses a transdermal adhesive composition
- a transdermal adhesive composition comprising a washed polymerization reaction products of at least two ethylenically unsaturated monomers, and at least one pharmaceutically active compound which are susceptible to oxidative degradations.
- PCT Application Number WO 2012/087047 discloses a percutaneous absorption preparation comprising styrene-isoprene-styrene-block copolymer as an adhesive and rivastigmine, which provides an improved stability and potency of rivastigmine.
- U.S. Patent Application Number 2010/0087768 discloses a monolithic device for transdermal administration of pharmaceutical active ingredients which are liquid at room temperature.
- the composition contains an acrylic polymer pressure-sensitive adhesive without cross-linking agent, and a non-volatile co-adjuvant selected from squalene and triethylcitrate.
- the composition provides a good adhesion property, and minimizes loss of drug during manufacture.
- U.S. Patent Number 7,335,379 discloses a transdermal non-occlusive, semi-solid pharmaceutical formulation comprising rivastigmine and a solvent system containing a glycol, monoalkyl ether of diethylene glycol and a mixture of lower alcohols and water.
- the solvent system is present in an amount sufficient to solubilize rivastigmine and inhibit its crystallization when applied on the skin.
- U.S. Patent Number 7,638,140 discloses a free base material which is suitable for use in an adhesive and or in a transdermal patch containing an acrylic polymeric adhesive which includes a C4-C12 alkyl acrylate, a C1-C3 alkyl acrylate hardening monomer; a functionalizing monomer which facilitates crosslinking; and a highly plasticizing drug component.
- TTS transdermal therapeutic system
- a backing layer comprising one or more pharmaceutically acceptable ingredients, antioxidant, polymers, and adhesive layer comprising a silicon polymer and a tackifier.
- U.S. Patent Number 6,660,295 discloses a package for transdermal delivery device, which prevents oxidative degradation of active ingredient during storage.
- the package contains a transdermal drug delivery device comprising a drug reservoir layer positioned between a release liner and a backing layer, at least one of said release liner and said backing layer being non-occlusive; and a degradation protectant.
- a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof comprising a backing layer, an adhesive material, one or more pharmaceutically acceptable excipients and a release liner, wherein the drug delivery system is free from an antioxidant.
- a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof comprising an adhesive material, wherein the drug delivery system is free from an antioxidant and the adhesive material is present in an amount from about 30 to about 90% by weight of the composition.
- a stable transdermal drug delivery system comprising a backing layer; an adhesive layer comprising rivastigmine or a pharmaceutically acceptable salt thereof, an adhesive material, one or more pharmaceutically acceptable excipients; and a release liner, wherein the adhesive layer releasably fixes the transdermal drug delivery system to a patient skin and the drug delivery system is free from an antioxidant.
- Embodiments of the stable transdermal drug delivery system may include one or more of the following features.
- the stable transdermal drug delivery system may include one or more pharmaceutical excipients suitable for topical application selected from penetration enhancers, fillers, plasticizers, tackifiers, surfactants, humectants, or a combination thereof.
- a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof wherein the drug delivery system is present in the form of matrix or reservoir.
- a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof wherein the drug delivery system is free from an antioxidant and retains at least 90% of the potency of rivastigmine in the composition after storage for three months at accelerated storage condition (40°C ⁇ 2°C/75%RH ⁇ 5% RH).
- a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof wherein the drug delivery system is free from an antioxidant and exhibits no significant difference in rate and extent of absorption of rivastigmine as compared to commercially available formulation of rivastigmine marketed under the trade name Exelon®.
- a process of preparing a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system is free from an antioxidant comprises preparing a drug mass comprising rivastigmine or a pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients, casting the drug mass onto a release liner film, drying the release liner to form ah adhesive layer on release liner, and laminating a backing layer to the adhesive layer.
- a method of treating mild to moderate dementia of the alzheimer's type or mild to moderate dementia associated with parkinson's disease in a patient comprising administering to the patient a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system is free from an antioxidant.
- free from an antioxidant refers to a transdermal pharmaceutical composition, to which no antioxidant has been added for tine purpose of preventing a pharmaceutical active compound susceptible to oxidative degradation from forming total impurities in excess of 1% during storage-stability period.
- the transdermal drug delivery system of the present invention may show less than 1.0% degradation products as proposed by regulatory agency guidelines for stability testing at accelerated storage conditions (40°C ⁇ 2°C/75%RH ⁇ 5%RH) for three months.
- the present invention relates to a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof comprising a backing layer, an adhesive material, one or more pharmaceutically acceptable excipients and a release liner, wherein the drug delivery system is free from an antioxidant.
- transdermal drug delivery system refers to an administration of a drug to the skin surface of an individual, so that the drug passes through the skin tissue and into the individual's blood stream.
- 'rivastigmine' is used in broad sense to include not only the rivastigmine per se but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms.
- the amount of rivastigmine or a pharmaceutically acceptable salt thereof in the compositions may range from about 1 to about 40% by weight of the composition, preferably from about 5 to about 20% by weight of the composition.
- the dosage amount of rivastigmine or a pharmaceutically acceptable salt thereof in the composition may present from about 2 mg to about 25 mg, preferably from about 4 mg to about 15 mg.
- the transdermal pharmaceutical drug delivery system comprising rivastigmine or a pharmaceutically acceptable salt thereof is present in the form of patch, film, or plaster.
- antioxidant refers to a substance which lowers the level or prevents the formation of active radicals or active forms of oxygen.
- the transdermal drug delivery system free from antioxidants are selected from, but not limited to tocopherol and its esters such as tocopherol acetate, a-tocopherol, ascorbyl palmitate, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, propyl gallate, polyphenolic antioxidants, sodium sulfite, sodium bisulfite, sodium metabisulfite, thiogly colic acid, monothioglycerol, L-cysteine or a combination thereof.
- adheresive material refers to a viscoelastic material which adheres instantaneously to most substrates with the application of very slight pressure and remains permanently tacky.
- adhesive can be interchangeably used as "pressure-sensitive adhesive", if it has the properties of pressure-sensitive adhesive per se or function as a pressure-sensitive adhesive.
- An “adhesive” as used herein means any natural or synthetic material that is capable of sticking to the site of topical application.
- the adhesives must be biocompatible and non-irritating. It is also important that the adhesive should be selected such that it is compatible with the other components of the therapeutic adhesive formulation of the present invention.
- Suitable adhesive materials are selected from, but not limited to one or more, polyisobutylene, acrylates, silicones, polyisoalkylenes, polyether block amide copolymers polybutadiene, styrene-butadiene (or isoprene)-styrene block copolymer rubber, vinyl- based high molecular weight materials such as polyvinyl alkyl ether, polyvinyl acetate, ethylenevinylacetate copolymers, a partially saponified product of polyvinyl acetate, polyvinyl alcohol and polyvinyl pyrrolidone, polyurethane or a combination thereof.
- the polyisobutylene adhesives may contain blend of two different types of polyisobutylene having a different molecular weights.
- the high molecular weight polyisobutylene may range from about 450,000 to about 2,100,000 viscosity average molecular weight and a low molecular weight polyisobutylene may range from about 1,000 to about 450,000 viscosity average molecular weight
- the two polyisobutylenes with different molecular weight can be mixed with each other wherein the ratio of the polyisobutylene having the higher molecular weight to the polyisobutylene having the lower molecular weight is in the range from about 0.05:1 to about 20:1, preferably from about 0.5:1 to about 2:1, more preferably from about 1:1.
- Preferred polyisobutylenes are available commercially under the trade name of DuroTak ® 87-617A, DuroTak ® 87-608 A, DuroTak® 87-6908A from National Starch and the others are under the trade name of Vistanex®.
- the acrylic adhesives includes cross-linked and uncross-linked acrylic copolymers selected from polymethacrylate such as butyl acrylate, ethyl hexyl acrylate, vinyl acetate, (meth)acrylic acid such as butyl (meth)acrylate, pentyl (meth)acrylate, hexyl (meth)acrylate, .
- acrylate polymer are available commercially under the trade name Gelva® brand, e.g. Gelva® 3011 or DuroTak® brand available from National Starch and Chemical Company, Zutphen, Holland, e.g.
- DuroTak® 202A DuroTak® 608, DuroTak® 4202, DuroTak® 4287, DuroTak® 2510, DuroTak® 617 A, DuroTak® 87-2353, DuroTak® 87-2852, DuroTak® 87-2287, DuroTak® 87-2353, DuroTak® 387-2051 or DuroTak® 387-2052.
- the silicon adhesive refers to a polydimethylsiloxane based polymers. Suitable silicone adhesives are commercially available under the trademarks BIO-PSA® X7-3027, BIO-PSA® X7-4503, BIO-PSA ® X7-4603, BIO-PSA® X7-4301, BIO-PSA® X7-4303, BIO-PSA ® X7-4919, BIO-PSA ® X7-2685, and BIO-PSA ® X7-3122 by Dow Corning Corporation, Medical Products, Midland, Mich.
- the adhesive materials may present in an amount from about 30 to 90% by weight, preferably from about 50 to about 80% by weight, more preferably from about 65% to about 75% by weight.
- the ratio of the amount of adhesive material to rivastigmine or a pharmaceutically acceptable salt thereof in the composition may ranges from about 1:20 to about 20:1 in order to achieve the desire transdermal properties.
- a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof comprising polyisobutylene, one or more pharmaceutically acceptable excipients and a release liner, wherein the drug delivery system is free from an antioxidant.
- the transdermal drug delivery system comprises one or more pharmaceutical excipients suitable for topical application selected from penetration enhancers, fillers, plasticizers, tackifiers, surfactants, humectants, or a combination thereof.
- Suitable penetration enhancers may be selected from, but not limited to 1- dodecylazacycloheptan-2-one(azone), N,N-diethyl-m-toluamide (DEET), mineral oil, polyhydric alcohols (for example propylene glycol, glycerol, dipropylene glycol), fatty acids and esters thereof (for example oleic acid, ethyl oleate, glyceryl monolaurate, ethyl palmitate), isopropyl myristate, lactic acid, lactic acid esters, monoglycerides, triacetin, methyl laurate, transcutanol, dibutylsebacate, lauramide diethanolamine, propylene glycoisostearate, triglycerides, AMIFAT (derived from glycerin, oleic acid and 2- pyrrolidone-5-carboxylic acid) or a combination thereof.
- the amount of penetration enhancers in the composition range
- Suitable fillers are selected from, but not limited to metal oxides (such as zinc oxide and titanium oxide), metal salts (such as calcium carbonate, magnesium carbonate and zinc stearate), silicic acid compounds (such as kaolin, talc, bentonite, colloidal silicone dioxide, hydrous silica, aluminum silicate, magnesium silicate and magnesium aluminometasilicate), metal hydroxides (such as aluminum hydroxide) or a combination thereof.
- the fillers may present in an amount from about 1% to about 10% by weight.
- plasticizer refers to compounds that provide flexibility to the pharmaceutical composition. Suitable plasticizers are selected from, but not limited to mineral oil, citric acid esters, triacetin, saturated triglycerides, triethyl citrate, acetyl tributyl citrate, low molecular weight hydrocarbons or a combination thereof, that act to plasticize adhesives and increase their permeability to the agent being delivered.
- the plasticizers may present in an amount from about 1% to about 20% by weight, preferably from about 5 to 15% about by weight.
- the amount and type of plasticizers required may depend on a number of factors like drug content, and the amount of adhesive materials.
- the weight ratio of rivastigmine or a pharmaceutically acceptable salt thereof to plasticizer in the composition preferably ranges from about 1:0.25 to about 1:3.
- Suitable surfactants are selected from, but not limited to polysorbates, their ether ethoxylates, produced by reaction of sorbitan esters with ethylene oxide, polyoxyethylene alkyl phenol, polyoxyethylene cetyl ether, polyoxyethylene alkyl-aryl ether, polyoxyethylene monolaurate, polyoxyethylene vegetable oil, polyoxyethylene sorbitan monolaurate, polyoxyethylene esters or mixed fatty and resin acids, polyoxyethylene sorbitol lanolin derivative, polyoxyethylene tridecylether, polyoxyethylene sorbitan esters of mixed fatty and resin acids, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene monostearate, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene tridecyl ether, polyoxyethylene fatty alcohol, polyoxyethylene alkyl amine, polyoxyethylene glycol monopalmitate, polyoxyethylene sorbitan monopalmitate, polyoxy
- tackifier refers to an agent that improves the adhesive strength of the adhesive layer to the skin or mucosa.
- Suitable tackifiers are selected from, but not limited to aliphatic hydrocarbons, aromatic hydrocarbons, mixed aliphatic and aromatic hydrocarbons, substituted aromatic hydrocarbons, highly hydrogenated resin, terpene resin, petroleum resin, phenolic resin, xylene resin or a combination thereof.
- the plasticizers may present in an amount from about 1 % to about 20% by weight, preferably from about 5 to 15% about by weight.
- Suitable humectants are selected .from, but not limited to glycerol, propylene glycol, polyethylene glycol, 1,3-butanediol and D-sorbitol solution or a combination thereof.
- the humectant may present in an amount from about 5% to about 70% by weight, preferably from about 10% to about 60% by weight, more preferably from about 30% to about 50% by weight.
- the solvents used in the present invention for dissolving the substantial amount of drug substance are selected from aqueous or non-aqueous solvents.
- Non-aqueous solvents are selected from organic or inorganic solvents which include aromatic hydrocarbons such as toluene and xylene, aliphatic hydrocarbons such as acetone, heptane and hexane, alcohols such as methanol, ethanol, and isopropyl alcohol, aliphatic esters such as ethyl acetate or a combination thereof.
- the amount of solvents used in the present invention may depend on the drug content.
- the transdermal drug delivery system of the present invention is in the form of matrix type or reservoir type system.
- transdermal drug delivery system may be present of single-layer drug in adhesive matrix, multi-layer drug in adhesive matrix, matrix-dispersion system, matrix-diffusion system, multi- laminate system, membrane controlled reservoir system, micro-reservoir system, multi- reservoir system, and the like.
- the process of preparing the transdermal drug delivery system comprises the steps of preparing a drug mass comprising rivastigmine or a pharmaceutically acceptable salt thereof, adhesive materials and one or more pharmaceutically acceptable excipients; casting the drug mass onto a release liner film; drying the release liner and the drug mass to form a layer on release liner; laminating a backing layer to the adhesive layer; slitting and trimming the laminated coated layer; and die-cutting the laminate into dosage units using fixed size rotary dies.
- the process for preparing the transdermal drug delivery system comprises the steps of dissolving or dispersing rivastigmine or a pharmaceutically acceptable salt thereof with a one or more adhesive and one or more pharmaceutically acceptable excipients; applying the drug mass on the surface of release- controlling membrane made up from porous or non-porous materials and drying the drug mass; subsequently casting the drug mass onto the release liner; laminating the backing layer onto the upper surface of drug mass; slitting and trimming the laminated coated layer; and die-cutting the laminate into dosage units using fixed size rotary dies.
- the transdermal drug delivery system of the present invention retains at least 90% of the potency of rivastigmine in the composition after storage for six months at accelerated storage conditions (40°C ⁇ 2°C/75%RH ⁇ 5%RH) and at long-term storage conditions (30°C ⁇ 2°C/65%RH ⁇ 5%RH).
- the drug content in the composition does not differ from the label claim range of 90%-110% as specified by regulatory agency guidelines during stability period.
- the transdermal composition exhibits less than 1% of total impurities during the storage period for at least three months, six months, and twelve months.
- the transdermal drug delivery system is free from an antioxidant and exhibits no significant difference in rate and extent of absorption of rivastigmine or pharmaceutically acceptable salts thereof as compared to commercially available formulation of rivastigmine marketed under the trade name Exelon ® .
- the transdermal drug delivery system of the present invention comprising rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system exhibits an area under the curve (AUCo-t) from about 80 ng.hr/ml to about 160 ng.hr/ml, preferably from about 100 ng.hr/ ml to about 130 ng.hr/ ml.
- AUCo-t area under the curve
- the transdermal drug delivery system of the present invention comprising rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system exhibits a peak plasma concentration (C ma x) from about 2 ng/ ml to about 8 ng/ ml, preferably from about 4 ng/ ml to about 6 ng/ ml.
- the transdermal drug delivery system of the present invention comprising rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system exhibits time to achieve maximum concentration time (T max ) from about 8 to about 24 hours, preferably from about 12 to about 16 hours.
- T max maximum concentration time
- the transdermal drug delivery system minimizes skin irritation while maintaining high transdermal flux of rivastigmine.
- the transdermal drug delivery system of the present invention provides a flux rate of rivastigmine ranging from about 10 g/cm 2 .hr to about 50 ⁇ g/cm 2 .hr, preferably from about 20 ⁇ g/cm 2 .hr to about 30 ⁇ g/cm 2 .hr.
- the transdermal drug delivery system provides a drug release for a period of 24 hours after application.
- the transdermal drug delivery system of the present invention is intended to be applied once a day.
- the patch or film may be applied to upper or lower back, upper arm or chest.
- the thickness of the transdermal drug delivery system of present invention is intended to be higher to dissolve the substantial amount of rivastigmine during application period.
- the thickness of the transdermal drug delivery system may range from about 500 ⁇ to 1000 ⁇ , preferably from about 700 ⁇ to 900 ⁇ .
- the surface area of the transdermal drug delivery system is sufficient to maintain the effective contact with the skin during administration and also provides an intended drug delivery rate.
- the surface area of the transdermal drug delivery system may range from about 2 cm 2 to 30 cm 2 , preferably from about 5 cm 2 to 20 cm 2 .
- the backing layer is selected from woven or non-woven fabric materials.
- the backing layer serves as the upper layer of the device during use and functions as the primary structural element of the device.
- the backing layer of the present invention is soft, flexible, and has the multi-directional stretchable properties. When the external tensile force is applied, the backing layer is capable of stretching and, when the tensile force is removed, it has the capacity to return in the original position.
- the backing film provides mechanical support to the drug-adhesive matrix formulation. It also provides physical integrity to the system, maintenance of the physical dimensions and shape of the formulation which prevents direct contact of patch formulation with the environment. Suitable materials for backing layer are selected from natural or synthetic polymeric.
- a suitable natural polymeric material is selected from, but not limited to cellulose, silk, cotton and a suitable synthetic polymeric material is selected from, but not limited to poly inyl chloride, polyurethane, polyester, polyamide, polypropylene and the like.
- the thickness of backing layer may range from about 150 ⁇ to about ⁇ , preferably from about to 800 ⁇ .
- Suitable backing layer are selected from, but not limited to Scotchpak ® 9732, Scotchpak® 9727, Scotchpak® 1109, Scotchpak® 9730, Scotchpak® 9733, Scotchpak ® 9735, Scotchpak ® 9736, Scotchpak® 9738, Scotchpak ® 9757, CoTran ® 9700, CoTran ® 9708, CoTran® 9718, CoTran® 9719, CoTran® 9720, and CoTran ® 9722.
- the backing layer may be coated with polymeric materials to maintain the adhesiveness of the patch on the skin.
- the polymeric materials used for coating are selected from, but not limited to acrylates, polyisobutylenes, silicones, ethylene vinyl acetate copolymers or a combination thereof.
- the backing layer may further be coated with foam coating to form modified backing layer.
- the foam coating materials used are selected from, but not limited to Volara Foam type coating, e.g. Volara Foam Type 6EO.
- the adhesiveness property of the transdermal compositions may be evaluated by various methods, but not limited to a cold-flow method.
- a cold-flow method the adhesiveness result is evaluated at specific interval of time for a period of 24 hours with different scoring grades (score 0, 1, 2, 3, 4).
- the compositions of the present invention may have shown good adhesive property at the end of 24 hours period.
- the skin irritancy effect of the transdermal composition may be evaluated by use of skin irritation study (primary skin irritation index - score 0, 1, 2, 3, and 4).
- the composition of the present invention may not cause significant irritation during the 24 hours period after application.
- the result may be evaluated at different time intervals like at an interval of 30 minutes after application of the composition and after 24 hours of application.
- the release liner may be a disposable element which serves to protect the pharmaceutical composition prior to its application.
- the release liner is produced from a material impermeable to drug, and adhesive. This release liner may be easily stripped away from the adhesive.
- a preferred release liner is made of fluoro polymer coated polyester, or polyethylene terephthalate (PET) foil.
- PET polyethylene terephthalate
- the thickness of release liner may range from about 25 ⁇ to 250 ⁇ , e.g. 50 ⁇ thickness PET film, may be applied over the pharmaceutical composition.
- Suitable release liner are selected from, but not limited to Scotchpak ® and Loparex® grades like Scotchpak ® 1022, Scotchpak® 9741, Scotchpak ® 9742, Scotchpak ® 9744, Scotchpak ® 9748, Loparex ® 48015, Loparex® 48011, and Loparex ® 48036.
- the release liner may be silicone-coated.
- Said coating is preferably formed of any fluorosilicone compound which is conventionally used in the art, e.g a polyfluoroalkylsiloxane. It is particularly preferred to employ such a fluorosilicone coating when the adhesive used to affix the pharmaceutical composition to the release liner is not itself a silicone adhesive.
- the transdermal patches or films are typically packaged in unit dose pouches where a single patch is present inside a sealed and printed pouch.
- Pouching materials of the present invention are multi-laminate films where the outermost layer is printable and inner-most layer is heat sealable layer with a protective foil layer in between to provide barrier function and may devoid of the oxygen scavengers, desiccants, or any other stabilizing materials.
- the selected pouching materials have characteristics of acceptable heat sealability, protected during stability and transportation.
- transdermal drug delivery system aforementioned may be conveniently formed in continuous sheets and may be cut into patches or films of any desirable size or configuration before use.
- the method of delivering the pharmaceutically active compound to a mammal comprising the steps of: providing a transdermal adhesive composition according to any one of above composition; positioning the transdermal adhesive composition on the skin of the mammal; and allowing the composition to remain on the skin for a time sufficient to permit systemic delivery of the pharmaceutically active compound and/or achieve the desired therapeutic result.
- the period of time for such treatment can be between about 6 hours and about 14 days, typically between about 1 day and about 7 days, and more typically between about 1 day and about 4 days.
- the invention provides a method of heating mild to moderate dementia of the alzheimer's type or mild to moderate dementia associated with parkinson's disease in a patient, comprising administering to said patient a stable pharmaceutical composition of rivastigmine or pharmaceutically acceptable salt thereof according to the present invention.
- ScotchPak 1022 (Fluoropolymer 263.42 25.135 cm 2
- Heptane was taken into container and the rivastigmine was added into it and stirred for a few minutes. Then, light mineral oil, polyisobutylene and colloidal silicone dioxide were added in the resulting solution and again was stirred.
- Polyisobutylene was coated on a paper release liner, dried using a coating and drying machine and then was laminated by scotchpak 9757 (PET) using laminator.
- the drug blend was finally coated on a release liner (Scotchpak 1022) and dried in a coating and drying machine and then laminated by modified backing using laminator by de-laminating the paper release liner.
- the laminate is slit in 3 daughter rolls. The daughter rolls are placed into the die-cutting machine and converted into dosage unit of 16 cm 2 active area with 25.135 cm 2 release liner area.
- the resulting patches were finally packaged in a pouch or bag.
- the amount of the impurities measured in the formulation after the storage period indicates that the formulation of the invention is stable under stress conditions.
Abstract
The present invention relates to a stable transdermal pharmaceutical drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, which is free from an antioxidant. In particularly, the present invention relates to a stable transdermal pharmaceutical drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, which provides an enhanced absorption of drug through skin, and remains stable during a longer storage period. In addition, the present invention relates to a method of treatment of mild to moderate dementia of alzheimer's type and mild to moderate dementia of parkinson's type diseases.
Description
STABLE TRANSDERMAL PHARMACEUTICAL DRUG DELIVERY SYSTEM COMPRISING RIVASTIGMINE
FIELD OF THE INVENTION
The present invention relates to a stable transdermal pharmaceutical drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, which is free from an antioxidant. In particularly, the present invention relates to a stable transdermal pharmaceutical drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, which provides an enhanced absorption of drug through skin, and remains stable during a longer storage period. In addition, the present invention relates to a method of treatment of mild to moderate dementia of alzheimer's type and mild to moderate dementia of parkinson's type diseases.
BACKGROUND OF THE INVENTION
Rivastigmine is a reversible cholinesterase inhibitor (parasympathomimetic or cholinergic agent) that has been approved for the treatment of mild to moderate dementia of the alzheimer's type, and mild to moderate dementia associated with parkinson's disease.
Chemically it is known as (S) -N-ethyl-3- [(1- dimethylamino) ethyl] -N-methyl henyl carbamate and can be represented by following chemical structure -
Rivastigmine is known to be susceptible to degradation by oxygen from the environmental oxidation. Various pharmaceutical compositions comprising rivastigmine has been proposed in the prior art, claiming the use of antioxidants, particular carriers or excipients and packaging material containing oxygen scavengers to stabilize the formulation.
GB Patent Number 2203040 discloses transdermal composition of rivastigmine containing mixture of Eudragit E 100, DuroTak 280 - 2416 polymers and a plasticizer Brij 97. Such composition was found to degrade, possibly by oxidative degradation, despite the formation of an occlusive polymer matrix around the rivastigmine and its storage in air tight packaging.
U.S. Patent Number 6,335,031 and 6,660,295 disclose a pharmaceutical composition comprising rivastigmine in free base or acid addition salt form and an antioxidant to prevent oxidative degradation of rivastigmine. Such formulations found to be stable for a longer period of time.
PCT Application Number WO 2012/012417 discloses a transdermal adhesive composition comprising a washed polymerization reaction products of at least two ethylenically unsaturated monomers, and at least one pharmaceutically active compound which are susceptible to oxidative degradations.
PCT Application Number WO 2012/087047 discloses a percutaneous absorption preparation comprising styrene-isoprene-styrene-block copolymer as an adhesive and rivastigmine, which provides an improved stability and potency of rivastigmine.
U.S. Patent Application Number 2010/0087768 discloses a monolithic device for transdermal administration of pharmaceutical active ingredients which are liquid at room temperature. The composition contains an acrylic polymer pressure-sensitive adhesive without cross-linking agent, and a non-volatile co-adjuvant selected from squalene and triethylcitrate. The composition provides a good adhesion property, and minimizes loss of drug during manufacture.
U.S. Patent Number 7,335,379 discloses a transdermal non-occlusive, semi-solid pharmaceutical formulation comprising rivastigmine and a solvent system containing a glycol, monoalkyl ether of diethylene glycol and a mixture of lower alcohols and water. The solvent system is present in an amount sufficient to solubilize rivastigmine and inhibit its crystallization when applied on the skin.
U.S. Patent Number 7,638,140 discloses a free base material which is suitable for use in an adhesive and or in a transdermal patch containing an acrylic polymeric adhesive which includes a C4-C12 alkyl acrylate, a C1-C3 alkyl acrylate hardening monomer; a functionalizing monomer which facilitates crosslinking; and a highly plasticizing drug component.
U.S. Patent Application Number 2007/0128263 discloses a transdermal therapeutic system (TTS) comprising a backing layer, a reservoir layer comprising one or more pharmaceutically acceptable ingredients, antioxidant, polymers, and adhesive layer comprising a silicon polymer and a tackifier.
U.S. Patent Number 6,660,295 discloses a package for transdermal delivery device, which prevents oxidative degradation of active ingredient during storage. The package contains a transdermal drug delivery device comprising a drug reservoir layer positioned
between a release liner and a backing layer, at least one of said release liner and said backing layer being non-occlusive; and a degradation protectant.
Currently, marketed transdermal formulation of rivastigmine is available under bade name of Exelon® and contains antioxidant vitamin E to prevent oxidative degradation of rivastigmine.
Thus in order to achieve and maintain stable transdermal formulations of rivastigmine, the prior art references emphasize on use of antioxidants, use of special copolymers and use of specialized packaging system, which leads to increase in cost of final formulation. Moreover, in an attempt to render the desired stability, for example devising the transdermal formulation by proper selection of suitable polymers and excipients, resulting formulations may show less inter-individual variation with regard to plasma concentrations of rivastigmine required to produce a therapeutic benefit without unacceptable side effects.
Hence there still remains a need for alternative transdermal formulations of rivastigmine in order to achieve desired stability and also to improve compliance, adhesion, tolerability and/ or safety.
SUMMARY OF THE INVENTION
In one general aspect, there is provided a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system is free from an antioxidant.
In another general aspect, there is provided a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof comprising a backing layer, an adhesive material, one or more pharmaceutically acceptable excipients and a release liner, wherein the drug delivery system is free from an antioxidant.
In another general aspect, there is provided a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof comprising an adhesive material, wherein the drug delivery system is free from an antioxidant and the adhesive material is present in an amount from about 30 to about 90% by weight of the composition.
In another general aspect, there is provided a stable transdermal drug delivery system comprising a backing layer; an adhesive layer comprising rivastigmine or a pharmaceutically acceptable salt thereof, an adhesive material, one or more pharmaceutically acceptable excipients; and a release liner, wherein the adhesive layer
releasably fixes the transdermal drug delivery system to a patient skin and the drug delivery system is free from an antioxidant.
Embodiments of the stable transdermal drug delivery system may include one or more of the following features. For example, the stable transdermal drug delivery system may include one or more pharmaceutical excipients suitable for topical application selected from penetration enhancers, fillers, plasticizers, tackifiers, surfactants, humectants, or a combination thereof.
In another general aspect, there is provided a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system is present in the form of matrix or reservoir.
In another general aspect, there is provided a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system is free from an antioxidant and retains at least 90% of the potency of rivastigmine in the composition after storage for three months at accelerated storage condition (40°C ± 2°C/75%RH ± 5% RH).
In another general aspect, there is provided a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system is free from an antioxidant and exhibits no significant difference in rate and extent of absorption of rivastigmine as compared to commercially available formulation of rivastigmine marketed under the trade name Exelon®.
In another general aspect, there is provided a process of preparing a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system is free from an antioxidant, the process comprises preparing a drug mass comprising rivastigmine or a pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients, casting the drug mass onto a release liner film, drying the release liner to form ah adhesive layer on release liner, and laminating a backing layer to the adhesive layer.
In another general aspect, there is provided a method of treating mild to moderate dementia of the alzheimer's type or mild to moderate dementia associated with parkinson's disease in a patient, comprising administering to the patient a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system is free from an antioxidant.
The details of one or more embodiments of the present invention are set forth in the description below. Other features, objects and advantages of the invention will be apparent from the description. DETAILED DESCRIPTION OF THE INVENTION
The inventors of the present invention have found, in contrary to the teaching of the prior art that, it is possible to develop stable transdermal formulations of rivastigmine without using an antioxidant. Such formulations unexpectedly demonstrated a significant stability when subjected to storage for three months at accelerated storage condition (40°C ± 2°C/75%RH ± 5%RH). Such formulations may not require specialized packaging system to preclude the degradation of rivastigmine.
In the absence of teaching/suggestion in the art about how to develop stable transdermal formulations of rivastigmine without employing an antioxidant, the inventors have devised a pharmaceutical composition of rivastigmine by proper selection of pharmaceutical excipients. Such formulations may also demonstrate less inter- individual variation with regard to plasma concentrations of rivastigmine required to produce a therapeutic benefit without unacceptable side effects.
The term "free from an antioxidant" refers to a transdermal pharmaceutical composition, to which no antioxidant has been added for tine purpose of preventing a pharmaceutical active compound susceptible to oxidative degradation from forming total impurities in excess of 1% during storage-stability period.
The transdermal drug delivery system of the present invention may show less than 1.0% degradation products as proposed by regulatory agency guidelines for stability testing at accelerated storage conditions (40°C ± 2°C/75%RH ± 5%RH) for three months.
The present invention relates to a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof comprising a backing layer, an adhesive material, one or more pharmaceutically acceptable excipients and a release liner, wherein the drug delivery system is free from an antioxidant.
The term "transdermal drug delivery system" refers to an administration of a drug to the skin surface of an individual, so that the drug passes through the skin tissue and into the individual's blood stream.
The term 'rivastigmine' is used in broad sense to include not only the rivastigmine per se but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers,
pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms.
The amount of rivastigmine or a pharmaceutically acceptable salt thereof in the compositions may range from about 1 to about 40% by weight of the composition, preferably from about 5 to about 20% by weight of the composition. The dosage amount of rivastigmine or a pharmaceutically acceptable salt thereof in the composition may present from about 2 mg to about 25 mg, preferably from about 4 mg to about 15 mg.
In another embodiment, the transdermal pharmaceutical drug delivery system comprising rivastigmine or a pharmaceutically acceptable salt thereof is present in the form of patch, film, or plaster.
The term "antioxidant" refers to a substance which lowers the level or prevents the formation of active radicals or active forms of oxygen. The transdermal drug delivery system free from antioxidants are selected from, but not limited to tocopherol and its esters such as tocopherol acetate, a-tocopherol, ascorbyl palmitate, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, propyl gallate, polyphenolic antioxidants, sodium sulfite, sodium bisulfite, sodium metabisulfite, thiogly colic acid, monothioglycerol, L-cysteine or a combination thereof.
The term "adhesive material" refers to a viscoelastic material which adheres instantaneously to most substrates with the application of very slight pressure and remains permanently tacky. The term "adhesive" can be interchangeably used as "pressure-sensitive adhesive", if it has the properties of pressure-sensitive adhesive per se or function as a pressure-sensitive adhesive. An "adhesive" as used herein means any natural or synthetic material that is capable of sticking to the site of topical application. The adhesives must be biocompatible and non-irritating. It is also important that the adhesive should be selected such that it is compatible with the other components of the therapeutic adhesive formulation of the present invention.
Suitable adhesive materials are selected from, but not limited to one or more, polyisobutylene, acrylates, silicones, polyisoalkylenes, polyether block amide copolymers polybutadiene, styrene-butadiene (or isoprene)-styrene block copolymer rubber, vinyl- based high molecular weight materials such as polyvinyl alkyl ether, polyvinyl acetate, ethylenevinylacetate copolymers, a partially saponified product of polyvinyl acetate, polyvinyl alcohol and polyvinyl pyrrolidone, polyurethane or a combination thereof.
The polyisobutylene adhesives may contain blend of two different types of polyisobutylene having a different molecular weights. The high molecular weight polyisobutylene may range from about 450,000 to about 2,100,000 viscosity average molecular weight and a low molecular weight polyisobutylene may range from about 1,000 to about 450,000 viscosity average molecular weight The two polyisobutylenes with different molecular weight can be mixed with each other wherein the ratio of the polyisobutylene having the higher molecular weight to the polyisobutylene having the lower molecular weight is in the range from about 0.05:1 to about 20:1, preferably from about 0.5:1 to about 2:1, more preferably from about 1:1. Preferred polyisobutylenes are available commercially under the trade name of DuroTak® 87-617A, DuroTak® 87-608 A, DuroTak® 87-6908A from National Starch and the others are under the trade name of Vistanex®.
The acrylic adhesives includes cross-linked and uncross-linked acrylic copolymers selected from polymethacrylate such as butyl acrylate, ethyl hexyl acrylate, vinyl acetate, (meth)acrylic acid such as butyl (meth)acrylate, pentyl (meth)acrylate, hexyl (meth)acrylate, . heptyl (meth)acrylate, octyl (meth)acrylate, nonyl (meth)acrylate, decyl (meth)acrylate, undecyl (meth)acrylate, dodecyl (meth)acrylate, and tridecyl (meth)acrylate, and copolymers of at least one of the above esters and other monomers copolymerizable therewith. Preferred acrylate polymer are available commercially under the trade name Gelva® brand, e.g. Gelva® 3011 or DuroTak® brand available from National Starch and Chemical Company, Zutphen, Holland, e.g. DuroTak® 202A, DuroTak® 608, DuroTak® 4202, DuroTak® 4287, DuroTak® 2510, DuroTak® 617 A, DuroTak® 87-2353, DuroTak® 87-2852, DuroTak® 87-2287, DuroTak® 87-2353, DuroTak® 387-2051 or DuroTak® 387-2052.
The silicon adhesive refers to a polydimethylsiloxane based polymers. Suitable silicone adhesives are commercially available under the trademarks BIO-PSA® X7-3027, BIO-PSA® X7-4503, BIO-PSA® X7-4603, BIO-PSA® X7-4301, BIO-PSA® X7-4303, BIO-PSA® X7-4919, BIO-PSA® X7-2685, and BIO-PSA® X7-3122 by Dow Corning Corporation, Medical Products, Midland, Mich.
The adhesive materials may present in an amount from about 30 to 90% by weight, preferably from about 50 to about 80% by weight, more preferably from about 65% to about 75% by weight. The ratio of the amount of adhesive material to rivastigmine or a pharmaceutically acceptable salt thereof in the composition may ranges from about 1:20 to about 20:1 in order to achieve the desire transdermal properties.
In another embodiment, there is provided a stable transdermal drug delivery system of rivastigmine or a pharmaceutically acceptable salt thereof comprising polyisobutylene, one or more pharmaceutically acceptable excipients and a release liner, wherein the drug delivery system is free from an antioxidant.
The transdermal drug delivery system comprises one or more pharmaceutical excipients suitable for topical application selected from penetration enhancers, fillers, plasticizers, tackifiers, surfactants, humectants, or a combination thereof.
Suitable penetration enhancers may be selected from, but not limited to 1- dodecylazacycloheptan-2-one(azone), N,N-diethyl-m-toluamide (DEET), mineral oil, polyhydric alcohols (for example propylene glycol, glycerol, dipropylene glycol), fatty acids and esters thereof (for example oleic acid, ethyl oleate, glyceryl monolaurate, ethyl palmitate), isopropyl myristate, lactic acid, lactic acid esters, monoglycerides, triacetin, methyl laurate, transcutanol, dibutylsebacate, lauramide diethanolamine, propylene glycoisostearate, triglycerides, AMIFAT (derived from glycerin, oleic acid and 2- pyrrolidone-5-carboxylic acid) or a combination thereof. The amount of penetration enhancers in the composition ranges from about 1 to about 40% by weight of the composition.
Suitable fillers are selected from, but not limited to metal oxides (such as zinc oxide and titanium oxide), metal salts (such as calcium carbonate, magnesium carbonate and zinc stearate), silicic acid compounds (such as kaolin, talc, bentonite, colloidal silicone dioxide, hydrous silica, aluminum silicate, magnesium silicate and magnesium aluminometasilicate), metal hydroxides (such as aluminum hydroxide) or a combination thereof. The fillers may present in an amount from about 1% to about 10% by weight.
The term "plasticizer" refers to compounds that provide flexibility to the pharmaceutical composition. Suitable plasticizers are selected from, but not limited to mineral oil, citric acid esters, triacetin, saturated triglycerides, triethyl citrate, acetyl tributyl citrate, low molecular weight hydrocarbons or a combination thereof, that act to plasticize adhesives and increase their permeability to the agent being delivered. The plasticizers may present in an amount from about 1% to about 20% by weight, preferably from about 5 to 15% about by weight.
The amount and type of plasticizers required may depend on a number of factors like drug content, and the amount of adhesive materials. The weight ratio of rivastigmine or a pharmaceutically acceptable salt thereof to plasticizer in the composition preferably ranges from about 1:0.25 to about 1:3.
Suitable surfactants are selected from, but not limited to polysorbates, their ether ethoxylates, produced by reaction of sorbitan esters with ethylene oxide, polyoxyethylene alkyl phenol, polyoxyethylene cetyl ether, polyoxyethylene alkyl-aryl ether, polyoxyethylene monolaurate, polyoxyethylene vegetable oil, polyoxyethylene sorbitan monolaurate, polyoxyethylene esters or mixed fatty and resin acids, polyoxyethylene sorbitol lanolin derivative, polyoxyethylene tridecylether, polyoxyethylene sorbitan esters of mixed fatty and resin acids, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene monostearate, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene tridecyl ether, polyoxyethylene fatty alcohol, polyoxyethylene alkyl amine, polyoxyethylene glycol monopalmitate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene cetyl ether, polyoxyethylene oxypropylene stearate, polyoxyethylene lauryl ether, polyoxyethylene lanolin derivative, sodium oleate, quaternary ammonium derivative, potassium oleate, N-cetyl N-ethyl morpholinium ethosulfate, sodium lauryl sulfate or a combination thereof. The surfactants may present in an amount from about 1% to about 20% by weight, preferably from about 5 to 15% about by weight.
The term "tackifier" refers to an agent that improves the adhesive strength of the adhesive layer to the skin or mucosa. Suitable tackifiers are selected from, but not limited to aliphatic hydrocarbons, aromatic hydrocarbons, mixed aliphatic and aromatic hydrocarbons, substituted aromatic hydrocarbons, highly hydrogenated resin, terpene resin, petroleum resin, phenolic resin, xylene resin or a combination thereof. The plasticizers may present in an amount from about 1 % to about 20% by weight, preferably from about 5 to 15% about by weight.
Suitable humectants are selected .from, but not limited to glycerol, propylene glycol, polyethylene glycol, 1,3-butanediol and D-sorbitol solution or a combination thereof. The humectant may present in an amount from about 5% to about 70% by weight, preferably from about 10% to about 60% by weight, more preferably from about 30% to about 50% by weight.
The solvents used in the present invention for dissolving the substantial amount of drug substance are selected from aqueous or non-aqueous solvents. Non-aqueous solvents are selected from organic or inorganic solvents which include aromatic hydrocarbons such as toluene and xylene, aliphatic hydrocarbons such as acetone, heptane and hexane, alcohols such as methanol, ethanol, and isopropyl alcohol, aliphatic
esters such as ethyl acetate or a combination thereof. The amount of solvents used in the present invention may depend on the drug content.
In another embodiment, the transdermal drug delivery system of the present invention is in the form of matrix type or reservoir type system. Preferably, transdermal drug delivery system may be present of single-layer drug in adhesive matrix, multi-layer drug in adhesive matrix, matrix-dispersion system, matrix-diffusion system, multi- laminate system, membrane controlled reservoir system, micro-reservoir system, multi- reservoir system, and the like.
In another embodiment, the process of preparing the transdermal drug delivery system comprises the steps of preparing a drug mass comprising rivastigmine or a pharmaceutically acceptable salt thereof, adhesive materials and one or more pharmaceutically acceptable excipients; casting the drug mass onto a release liner film; drying the release liner and the drug mass to form a layer on release liner; laminating a backing layer to the adhesive layer; slitting and trimming the laminated coated layer; and die-cutting the laminate into dosage units using fixed size rotary dies.
In another embodiment, the process for preparing the transdermal drug delivery system comprises the steps of dissolving or dispersing rivastigmine or a pharmaceutically acceptable salt thereof with a one or more adhesive and one or more pharmaceutically acceptable excipients; applying the drug mass on the surface of release- controlling membrane made up from porous or non-porous materials and drying the drug mass; subsequently casting the drug mass onto the release liner; laminating the backing layer onto the upper surface of drug mass; slitting and trimming the laminated coated layer; and die-cutting the laminate into dosage units using fixed size rotary dies.
The transdermal drug delivery system of the present invention retains at least 90% of the potency of rivastigmine in the composition after storage for six months at accelerated storage conditions (40°C ± 2°C/75%RH ± 5%RH) and at long-term storage conditions (30°C ± 2°C/65%RH ± 5%RH). The drug content in the composition does not differ from the label claim range of 90%-110% as specified by regulatory agency guidelines during stability period. The transdermal composition exhibits less than 1% of total impurities during the storage period for at least three months, six months, and twelve months.
In another embodiment of the present invention, the transdermal drug delivery system is free from an antioxidant and exhibits no significant difference in rate and extent of absorption of rivastigmine or pharmaceutically acceptable salts thereof as compared to
commercially available formulation of rivastigmine marketed under the trade name Exelon®.
In another embodiment, the transdermal drug delivery system of the present invention comprising rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system exhibits an area under the curve (AUCo-t) from about 80 ng.hr/ml to about 160 ng.hr/ml, preferably from about 100 ng.hr/ ml to about 130 ng.hr/ ml.
In another embodiment, the transdermal drug delivery system of the present invention comprising rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system exhibits a peak plasma concentration (Cmax) from about 2 ng/ ml to about 8 ng/ ml, preferably from about 4 ng/ ml to about 6 ng/ ml.
In another embodiment, the transdermal drug delivery system of the present invention comprising rivastigmine or a pharmaceutically acceptable salt thereof, wherein the drug delivery system exhibits time to achieve maximum concentration time (Tmax) from about 8 to about 24 hours, preferably from about 12 to about 16 hours.
In another embodiment, the transdermal drug delivery system minimizes skin irritation while maintaining high transdermal flux of rivastigmine. The transdermal drug delivery system of the present invention provides a flux rate of rivastigmine ranging from about 10 g/cm2.hr to about 50 μg/cm2.hr, preferably from about 20 μg/cm2.hr to about 30 μg/cm2.hr. In the present invention, the transdermal drug delivery system provides a drug release for a period of 24 hours after application.
The transdermal drug delivery system of the present invention is intended to be applied once a day. The patch or film may be applied to upper or lower back, upper arm or chest.
The thickness of the transdermal drug delivery system of present invention is intended to be higher to dissolve the substantial amount of rivastigmine during application period. The thickness of the transdermal drug delivery system may range from about 500 μιη to 1000 μπ\, preferably from about 700 μιη to 900 μπι.
In another embodiment of the present invention, the surface area of the transdermal drug delivery system is sufficient to maintain the effective contact with the skin during administration and also provides an intended drug delivery rate. The surface
area of the transdermal drug delivery system may range from about 2 cm2 to 30 cm2, preferably from about 5 cm2 to 20 cm2.
In another embodiment, the backing layer is selected from woven or non-woven fabric materials. The backing layer serves as the upper layer of the device during use and functions as the primary structural element of the device. The backing layer of the present invention is soft, flexible, and has the multi-directional stretchable properties. When the external tensile force is applied, the backing layer is capable of stretching and, when the tensile force is removed, it has the capacity to return in the original position. The backing film provides mechanical support to the drug-adhesive matrix formulation. It also provides physical integrity to the system, maintenance of the physical dimensions and shape of the formulation which prevents direct contact of patch formulation with the environment. Suitable materials for backing layer are selected from natural or synthetic polymeric. A suitable natural polymeric material is selected from, but not limited to cellulose, silk, cotton and a suitable synthetic polymeric material is selected from, but not limited to poly inyl chloride, polyurethane, polyester, polyamide, polypropylene and the like. The thickness of backing layer may range from about 150μπ\ to about ΙΟΟΟμιη, preferably from about
to 800μηι.
Suitable backing layer are selected from, but not limited to Scotchpak® 9732, Scotchpak® 9727, Scotchpak® 1109, Scotchpak® 9730, Scotchpak® 9733, Scotchpak® 9735, Scotchpak® 9736, Scotchpak® 9738, Scotchpak® 9757, CoTran® 9700, CoTran® 9708, CoTran® 9718, CoTran® 9719, CoTran® 9720, and CoTran® 9722.
The backing layer may be coated with polymeric materials to maintain the adhesiveness of the patch on the skin. The polymeric materials used for coating are selected from, but not limited to acrylates, polyisobutylenes, silicones, ethylene vinyl acetate copolymers or a combination thereof. The backing layer may further be coated with foam coating to form modified backing layer. The foam coating materials used are selected from, but not limited to Volara Foam type coating, e.g. Volara Foam Type 6EO.
The adhesiveness property of the transdermal compositions may be evaluated by various methods, but not limited to a cold-flow method. In a cold-flow method, the adhesiveness result is evaluated at specific interval of time for a period of 24 hours with different scoring grades (score 0, 1, 2, 3, 4). The compositions of the present invention may have shown good adhesive property at the end of 24 hours period.
The skin irritancy effect of the transdermal composition may be evaluated by use of skin irritation study (primary skin irritation index - score 0, 1, 2, 3, and 4). The
composition of the present invention may not cause significant irritation during the 24 hours period after application. The result may be evaluated at different time intervals like at an interval of 30 minutes after application of the composition and after 24 hours of application.
The release liner may be a disposable element which serves to protect the pharmaceutical composition prior to its application. Typically the release liner is produced from a material impermeable to drug, and adhesive. This release liner may be easily stripped away from the adhesive. A preferred release liner is made of fluoro polymer coated polyester, or polyethylene terephthalate (PET) foil. The thickness of release liner may range from about 25μιη to 250μιη, e.g. 50μηι thickness PET film, may be applied over the pharmaceutical composition. Suitable release liner are selected from, but not limited to Scotchpak® and Loparex® grades like Scotchpak® 1022, Scotchpak® 9741, Scotchpak® 9742, Scotchpak® 9744, Scotchpak® 9748, Loparex® 48015, Loparex® 48011, and Loparex® 48036.
The release liner may be silicone-coated. Said coating is preferably formed of any fluorosilicone compound which is conventionally used in the art, e.g a polyfluoroalkylsiloxane. It is particularly preferred to employ such a fluorosilicone coating when the adhesive used to affix the pharmaceutical composition to the release liner is not itself a silicone adhesive.
In another embodiment, the transdermal patches or films are typically packaged in unit dose pouches where a single patch is present inside a sealed and printed pouch. Pouching materials of the present invention are multi-laminate films where the outermost layer is printable and inner-most layer is heat sealable layer with a protective foil layer in between to provide barrier function and may devoid of the oxygen scavengers, desiccants, or any other stabilizing materials. The selected pouching materials have characteristics of acceptable heat sealability, protected during stability and transportation.
The transdermal drug delivery system aforementioned may be conveniently formed in continuous sheets and may be cut into patches or films of any desirable size or configuration before use.
The method of delivering the pharmaceutically active compound to a mammal comprising the steps of: providing a transdermal adhesive composition according to any one of above composition; positioning the transdermal adhesive composition on the skin of the mammal; and allowing the composition to remain on the skin for a time sufficient
to permit systemic delivery of the pharmaceutically active compound and/or achieve the desired therapeutic result. The period of time for such treatment can be between about 6 hours and about 14 days, typically between about 1 day and about 7 days, and more typically between about 1 day and about 4 days.
In an embodiment, the invention provides a method of heating mild to moderate dementia of the alzheimer's type or mild to moderate dementia associated with parkinson's disease in a patient, comprising administering to said patient a stable pharmaceutical composition of rivastigmine or pharmaceutically acceptable salt thereof according to the present invention.
The invention is further illustrated by the following examples which are provided to be exemplary of the invention and do not limit the scope of the invention. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Example 1
Table 1
• Ingredients Qry./ unit Qry./ unit
(mg) (%w/w)
Rivastigmine 14.40 6.00
Polyisobutylene 169.20 70.50
Colloidal Silicon dioxide 25.20 10.50
Light mineral Oil 31.20 13.00
Heptane 0.00 0.00
Total 240.00 100
Modified Backing
Volara Foam Type 6EO 121.6 16.000 cm2
Polyisobutylene 24.0
ScotchPak 9757 32.0
Release Liner
ScotchPak 1022 (Fluoropolymer 263.42 25.135 cm2
coated Polyester Film)
Paper Release Liner — 25.135 cm2
Procedure:
Preparation of drug blend
Heptane was taken into container and the rivastigmine was added into it and stirred for a few minutes. Then, light mineral oil, polyisobutylene and colloidal silicone dioxide were added in the resulting solution and again was stirred.
Preparation of Modified Backing layer
Polyisobutylene was coated on a paper release liner, dried using a coating and drying machine and then was laminated by scotchpak 9757 (PET) using laminator.
The drug blend was finally coated on a release liner (Scotchpak 1022) and dried in a coating and drying machine and then laminated by modified backing using laminator by de-laminating the paper release liner. The laminate is slit in 3 daughter rolls. The daughter rolls are placed into the die-cutting machine and converted into dosage unit of 16 cm2 active area with 25.135 cm2 release liner area. The resulting patches were finally packaged in a pouch or bag.
The stability study of this formulation was conducted at accelerated storage conditions (40°C ± 2°C/75% RH ± 5% RH) and at long-term storage conditions (30°C ± 2°C/65%RH ± 5%RH) over a period of 6 months.
Assay data of Example 1:
Table 2
Stability data of Example 1 for impurities (1 Month, 3 Months and 6 Months! at accelerated and long-term storage conditions:
Table 3
The amount of the impurities measured in the formulation after the storage period indicates that the formulation of the invention is stable under stress conditions.
The pharmacokinetic study of transdermal patch containing rivastigmine of 16 cm2 was carried out in total 39 subjects and the data (example 1) are summarized as in Table 4.
Table 4
The in-vitro adhesion tests were also carried out for composition prepared as Example 1. The results of the tests are mentioned in Table 5 below.
Table 5
Properties Limit Actual value
Peel at 180° NLT lOg/mm 48
Tack NLT 10 g/mm2 37
Shear NLT 15 min 61
Release Force NMT lOOg/cm 6
Claims
A stable transdermal drug delivery system comprising a backing layer, rivastigmine or a pharmaceutically acceptable salt thereof, an adhesive material, one or more pharmaceutically acceptable excipients and a release liner, wherein the drug delivery system is free from an antioxidant.
The stable transdermal drug delivery system as claimed in claim 1, wherein rivastigmine or a pharmaceutically acceptable salt thereof is present in an amount from about 1 to about 40% by weight of the composition.
The stable transdermal drug delivery system as claimed in claim 1, wherein the adhesive material is selected from the group of polyisobutylene, acrylates, silicones, polyisoalkylenes, polyether block amide copolymers polybutadiene, styrene-butadiene (or isoprene)-styrene block copolymer rubber, vinyl-based high molecular weight materials such as polyvinyl alkyl ether, polyvinyl acetate, ethylenevinylacetate copolymers, a partially saponified product of polyvinyl acetate, polyvinyl alcohol and polyvinyl pyrrolidone, polyurethane or a combination thereof.
The stable transdermal drug delivery system as claimed in claim 1, wherein the adhesive material is present in an amount from about 30 to about 90% by weight of the composition.
The stable transdermal drug delivery system as claimed in claim 1, wherein the excipient is selected from the group of penetration enhancers, fillers, thickeners, plasticizers, tackifiers, surfactants, humectants, preservatives or a combination thereof.
The stable transdermal drug delivery system as claimed in claim 1, wherein the drug delivery system is present in the form of matrix or reservoir.
The stable transdermal drug delivery system as claimed in claim 1, wherein the drug delivery system exhibits no significant difference in rate and extent of
absorption of rivastigmine as compared to commercially available formulation of rivastigmine marketed under the trade name Exelon®.
8. The stable transdermal drug delivery system as claimed in claim 1, wherein the . drug delivery system retains at least 90% of the potency of rivastigmine in the composition after storage for six months at 40°C ± 2°C/75% RH ± 5% RH.
9. The stable transdermal drug delivery system as claimed in claim 1, wherein the backing layer is coated with polymeric material to form a modified backing layer.
10. The stable transdermal drug delivery system as claimed in claim 1, wherein the drug delivery system is used in the treatment of mild to moderate dementia of alzheimer's type and mild to moderate dementia of parkinson's type diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN128/MUM/2013 | 2013-01-15 | ||
| IN128MU2013 | 2013-01-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2014111790A2 true WO2014111790A2 (en) | 2014-07-24 |
| WO2014111790A3 WO2014111790A3 (en) | 2014-10-23 |
Family
ID=50114434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2014/000029 WO2014111790A2 (en) | 2013-01-15 | 2014-01-14 | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014111790A2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016112263A1 (en) * | 2015-01-09 | 2016-07-14 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
| EP3228309A4 (en) * | 2014-12-05 | 2018-07-11 | KM Transderm Ltd. | Adhesive sheet for attachment to skin and percutaneous absorption preparation using same |
| EP3845223A1 (en) * | 2018-08-31 | 2021-07-07 | SK Chemicals Co., Ltd. | Rivastigmine patch for long-term administration |
| US11179469B2 (en) * | 2017-04-28 | 2021-11-23 | Nitto Denko Corporation | Transdermal absorption preparation |
| EP3845224A4 (en) * | 2018-08-31 | 2022-06-01 | SK Chemicals Co., Ltd. | Rivastigmine patch for long-term administration |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2203040A (en) | 1987-03-04 | 1988-10-12 | Sandoz Ltd | Phenyl carbamates |
| US6335031B1 (en) | 1998-01-12 | 2002-01-01 | Novartis Ag | TTS containing an antioxidant |
| US6660295B2 (en) | 1997-09-30 | 2003-12-09 | Alza Corporation | Transdermal drug delivery device package with improved drug stability |
| US20070128263A1 (en) | 2005-12-01 | 2007-06-07 | Gargiulo Paul M | Transdermal therapeutic system |
| US7335379B2 (en) | 2003-10-10 | 2008-02-26 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US7638140B2 (en) | 1997-06-26 | 2009-12-29 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| US20100087768A1 (en) | 2008-10-02 | 2010-04-08 | Forlano Paula | Transdermal drug delivery system for liquid active ingredient |
| WO2012012417A1 (en) | 2010-07-21 | 2012-01-26 | 3M Innovative Properties Company | Transdermal adhesive compositions, devices, and methods |
| WO2012087047A2 (en) | 2010-12-24 | 2012-06-28 | Samyang Biopharmaceuticals Corporation | Percutaneous absorption preparation containing rivastigmine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5666087B2 (en) * | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Methods and compositions for the treatment of CNS related diseases |
| ES2545094T3 (en) * | 2010-12-14 | 2015-09-08 | Acino Ag | Transdermal therapeutic system for the administration of an active substance |
-
2014
- 2014-01-14 WO PCT/IB2014/000029 patent/WO2014111790A2/en active Application Filing
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2203040A (en) | 1987-03-04 | 1988-10-12 | Sandoz Ltd | Phenyl carbamates |
| US7638140B2 (en) | 1997-06-26 | 2009-12-29 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| US6660295B2 (en) | 1997-09-30 | 2003-12-09 | Alza Corporation | Transdermal drug delivery device package with improved drug stability |
| US6335031B1 (en) | 1998-01-12 | 2002-01-01 | Novartis Ag | TTS containing an antioxidant |
| US7335379B2 (en) | 2003-10-10 | 2008-02-26 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US20070128263A1 (en) | 2005-12-01 | 2007-06-07 | Gargiulo Paul M | Transdermal therapeutic system |
| US20100087768A1 (en) | 2008-10-02 | 2010-04-08 | Forlano Paula | Transdermal drug delivery system for liquid active ingredient |
| WO2012012417A1 (en) | 2010-07-21 | 2012-01-26 | 3M Innovative Properties Company | Transdermal adhesive compositions, devices, and methods |
| WO2012087047A2 (en) | 2010-12-24 | 2012-06-28 | Samyang Biopharmaceuticals Corporation | Percutaneous absorption preparation containing rivastigmine |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3228309A4 (en) * | 2014-12-05 | 2018-07-11 | KM Transderm Ltd. | Adhesive sheet for attachment to skin and percutaneous absorption preparation using same |
| US10314791B2 (en) | 2014-12-05 | 2019-06-11 | KM Transderm Ltd. | Adhesive sheet for attachment to skin and percutaneous absorption preparation using same |
| WO2016112263A1 (en) * | 2015-01-09 | 2016-07-14 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
| US11179469B2 (en) * | 2017-04-28 | 2021-11-23 | Nitto Denko Corporation | Transdermal absorption preparation |
| EP3845223A1 (en) * | 2018-08-31 | 2021-07-07 | SK Chemicals Co., Ltd. | Rivastigmine patch for long-term administration |
| EP3845223A4 (en) * | 2018-08-31 | 2022-06-01 | SK Chemicals Co., Ltd. | Rivastigmine patch for long-term administration |
| EP3845224A4 (en) * | 2018-08-31 | 2022-06-01 | SK Chemicals Co., Ltd. | Rivastigmine patch for long-term administration |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014111790A3 (en) | 2014-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2785117C (en) | Transdermal therapeutic system for administering rivastigmine or derivatives thereof | |
| JP6077596B2 (en) | Ropinirole-containing patch and its package | |
| KR101843966B1 (en) | Adhesive skin patch | |
| DK2468274T3 (en) | Transdermal therapeutic system for administration of an active substance | |
| AU2018203157A1 (en) | Transdermal drug delivery device | |
| JP4873871B2 (en) | Adhesives and patches | |
| JP5823510B2 (en) | Ropinirole-containing patch and its package | |
| TW201521796A (en) | Compositions and methods for transdermal delivery of tertiary amine drugs | |
| JPH09315957A (en) | Device for percutaneous therapy | |
| US20060257461A1 (en) | Multilayer galantamine delivery system with barrier against reservoir material flow | |
| JP5632577B2 (en) | Patch | |
| KR101942677B1 (en) | Adhesive plaster | |
| KR101766495B1 (en) | Fentanyl-containing adhesive preparation for external use | |
| WO2014111790A2 (en) | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine | |
| JP5738531B2 (en) | Patch | |
| US20170112781A1 (en) | Transdermal drug delivery systems with polyisobutylene face adhesive | |
| US20050175676A1 (en) | Patch | |
| JP6457486B2 (en) | Patch preparation | |
| US20140336253A1 (en) | Composition for transdermal administration of rivastigmine | |
| WO2013047410A1 (en) | Long-acting adhesive skin patch for treating alzheimer's disease, and method for producing same | |
| WO2014068600A1 (en) | Stable transdermal pharmaceutical drug delivery system comprising diclofenac | |
| JP6285820B2 (en) | Galantamine-containing transdermal absorption preparation | |
| JPWO2017094337A1 (en) | Patch | |
| JP6512905B2 (en) | Fentanyl-containing patch | |
| CN110913912A (en) | Non-repositionable patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14704888 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14704888 Country of ref document: EP Kind code of ref document: A2 |